<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849339</url>
  </required_header>
  <id_info>
    <org_study_id>184BE18028</org_study_id>
    <nct_id>NCT03849339</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the clinical trail is to evaluate the pharmacokinetics and safety/tolerability
      after oral administration of CKD-387 and D635 under fed condition in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 28, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Metformin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Maximum plasma concentration of Metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Metformin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Metformin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Area under the plasma concentration of Metformin-time curve from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Metformin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Time to reach maximum (peak) plasma concentration of Metformin following drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Metformin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Half-life of Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Metformin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Apparent clearance of Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Metformin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Apparent volume of distribution of Metformin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D635
Period 2: CKD-387</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-387
Period 2: D635</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-387</intervention_name>
    <description>Test drug</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D635</intervention_name>
    <description>Reference drug</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults aged 19 to 55 years

          2. Females must be menopause or surgical infertility

          3. Signed informed consent form

          4. Other inclusion criteria, as defined in the protocol

        Exclusion Criteria:

          1. History of clinically significant hepatic, renal, nervous, immune, respiratory,
             endocrine, hemato-oncology, cardiovascular systemic disease or psychosis disorder

          2. Clinical laboratory test values are outside the accepted normal range at Screening

               -  aspartate aminotransferase(AST), alanine aminotransferase(ALT) &gt; 1.25 times the
                  upper limit of the normal range

               -  Total Bilirubin &gt; 1.5 times the upper limit of the normal range

               -  creatine phosphokinase(CPK) &gt; 1.5 times the upper limit of the normal range

               -  estimated Glomerular Filtration Rate(eGFR, MDRD* formula) &lt; 60 mL/min/1.73m2
                  (*MDRD: Modification of Diet in Renal Disease)

               -  Positive reaction on following tests: Hepatitis B, Hepatitis C, human
                  immunodeficiency virus(HIV) and syphilis

               -  systolic blood pressure(SBP) â‰¥ 150 mmHg or &lt; 90 mmHg, diastolic blood
                  pressure(DBP) &gt; 100 mmHg or &lt; 50 mmHg

          3. Subject who smoke heavily or drink caffeine or alcohol continuously and who cannot
             discontinue smoking, caffeine or alcohol intake during hospitalization

          4. Participated in a clinical trial within 90 days prior to 1st IP dosing

          5. Not eligible to participate for the study at the discretion of Investigator

          6. Other exclusive inclusion criteria, as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park, Ph.D. M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

